For added information, visit BC Government Your Voice page
PharmaCare regularly reviews drugs to decide whether to cover them. PharmaCare considers the drug’s safety, how well it works, how much it costs, and how it compares to other, similar drugs. Another consideration is input from people with experience using the product under review and/or with the condition it would treat.
BC residents, caregivers and patient groups can complete a Your Voice survey to share their experiences and opinions about drugs and devices that PharmaCare is considering covering. A survey usually takes 15-20 minutes to complete.
The province of BC is now inviting input from the public regarding coverage for Maviret ® (glecaprevir-pibrentasvir tablets), a drug that can be used to treat acute and chronic hepatitis C infection in adults and pediatric patients 3 years of age and older and weighing ≥ 12 kg.
Hepatitis C is a liver infection caused by the hepatitis C virus. Acute hepatitis C is a shorter-term illness that occurs within the first six months of exposure, and if left untreated, can lead to liver damage.
With the approval of Maviret for acute and chronic hepatitis C infection by Health Canada in January of this year, healthcare providers are now empowered to start treatment for acute hepatitis C as soon as the diagnosis is made.
PAN will be completing a survey as a patient group. We encourage other PAN members who support people with lived and living experience of hepatitis C to consider registering as a patient group and completing the survey – becoming a recognized patient group is an easy process.
Individuals (patients, parents, caregivers) can also complete a survey and do not need to register. The deadline for completing the survey is Tuesday, June 23, 2026, at 11:59 PM.
BC residents may complete a Your Voice survey if they:
- Have the medical condition the drug would treat, or
- Are a caregiver for someone with the condition the drug would treat, or
- Represent a patient group for BC patients with the condition the drug would treat.
If you’re interested in learning more about how to add your thoughts, visit Your Voice page to learn more about the process, see sample surveys, and submit your views. Scroll to Glecaprevir-Pibrentasvir (Maviret®) and read the pdf on medication information, then click the link on the drug name.